Barrett's Esophagus Clinical Trials

A listing of Barrett's Esophagus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 349 clinical trials
UPCC 03418: A Phase 1 First in Human Open Label Dose Escalation Study of AMV564 a CD33 x CD3 Tandem Diabody in Patients with Relapsed or Refractory Acute Myeloid Leukemia

The purpose of this clinical research study is to find the highest tolerable dose that can be given to patients with AML, and to recommend a dose to be used in future studies. Another purpose of the study is to learn more about the safety of this drug and how …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Bone Water and Mineralization Measured by Nuclear Magnetic Resonance

All study participants will receive 1200 mg of calcium and 1000 units of Vitamin D. DXA, pQCT and MRI will be repeated at 12 and 24 months.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A study of human multi-sensory integration: A neurophysiologic correlate of conscious perception

After questions concerning study design are answered we will obtain consent for the participation in the study. On the day of the study, EEG cap will be applied for monitoring brain activity and IV will be placed for drug administration. Blood pressure, ECG, pulse oxymetry, and end-tidal CO2 (from nasal …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Study to Evaluate Imaging Feasibility, Safety and Diagnostic Performance Post Dosing of an Intraoperative Fluorescent Imaging Agent for Detection of Metastatic Lymph Nodes Primary Tumors and Tumor Margins in Patients with Solid Tumors

The main purpose of this study is to investigate whether ONM-100 can be used to image primary tumors and metastatic lymph nodes at time points earlier than 24 ±8 hours in patients undergoing routine surgery of their solid cancers and whether the diagnostic performance to detect metastatic lymph nodes can …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Targeting the Cholinergic Pathway in HIV-associated Inflammation and Cognitive Dysfunction

At the beginning and end of each treatment phase, inflammatory biomarkers and viral load will be assessed. Monocyte transcriptomics will also be assessed on a subset of the sample (n=60; 30/group). Neurocognition and clinical outcomes (e.g., QoL) will be measured at baseline and at 4-week intervals during each treatment phase.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Opioid Taper in Chronic Pain

Are you and your physician planning to taper your opioid dose? If so, you may be eligible to participate in a paid research study looking to evaluate how the perception of pain changes as opioid medication is tapered.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Trauma Induced Coagulapathy and Inflammation

Using a convenience sample technique, demographic data, physiologic data, fresh and residual blood samples, urine samples, and clinical variables will be collected over 5 days following traumatic injury. In addition to a computational model, ex vivo models using microfluidic devices and high resolution cellular respirometry, and nucleic acid analysis will …

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Long-Term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)

All participants will receive active study drug as described below, but their status (active or placebo) in the original MAVERICK-HCM study will remain blinded as the studies will be enrolling in parallel. Approximately 60 participants will be enrolled; enrollment must occur within 3 months of the participant completing MAVERICK-HCM.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase II Randomized Double-Blind Multicenter Multinational Placebo-Controlled Parallel-Groups Study to Evaluate the Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells for the Treatment of Subjects with Intermittent Claudication (IC)

Study termination at week 65 after first treatment. Approximately 150 subjects will be enrolled into this study in order to have 126 subjects completing the study. A target number of 44 subjects will be enrolled into each of the 2 x high dose and 2 x placebo groups (groups 2 …

  • 0 views
  • 19 Feb, 2024
  • 1 location
2 march edit9

Based on the Stage 1 analysis performed in November 2014, Arm 1 was chosen for expansion in Stage 2. Stage 2 dose will be 1-5x10xE8 transduced CART-19 cells. The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% …

  • 0 views
  • 19 Feb, 2024
  • 1 location